Determination of omeprazole and metabolites in plasma and urine by liquid chromatography.

No abstract is available for this paper.

• Publication year

  1984

• Venue

  Journal of Chromatography A

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/0378-4347(84)80042-0PMID 6480786
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Simultaneous high-performance liquid chromatographic analysis of omeprazole and its sulphone and sulphide metabolites in human plasma and urine.

  1983cited by this paper
• Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man.

  1983cited by this paper
• Differentiation among inhibitory actions of omeprazole, cimetidine, and SCN- on gastric acid secretion.

  1983cited by this paper
• Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+) ATPase

  1981cited by this paper

• Rectal Omeprazole in Infants With Gastroesophageal Reflux Disease: A Randomized Pilot Trial

  2020cites this paper
• Pharmacogenomics in and Its Influence on Pharmacokinetics

  2020cites this paper
• OXIDATIVE HYDROXYLATION OF OMEPRAZOLE IN HEALTHY SUBJECTS OF NIGER DELTA REGION BY THIN LAYER CHROMATOGRAPHY

  2018cites this paper
• Identification of the acid-induced degradation products of omeprazole and 5-hydroxyomeprazole by high-resolution mass spectrometry.

  2018cites this paper
• Different Chromatographic and Electrophoretic Methods for Analysis of Proton Pump Inhibitors (PPIs): A Review

  2015cites this paper
• Proton pump inhibitors: recent developments in analytical methodologies

  2015cites this paper
• An overview of the recent developments in analytical methodologies for determination of proton pump inhibitors in bulk drugs, pharmaceuticals and biological matrices.

  2014cites this paper
• CYP2C19 polymorphisms in drug metabolism and response

  2014cites this paper
• Population pharmacokinetics of omeprazole in a random Iranian population.

  2013cites this paper
• Pharmacogenomics in Drug Metabolizing Enzymes and Transporters

  2013cites this paper
• A comparison of the acid‐inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism

  2012cites this paper
• Clinical effects of proton pump inhibitors: Focus on pharmacogenetics, kinetics and dynamics

  2010influential citation
• Preconcentration and Quantitative Determination of Esomeprazole Magnesium Present in Water

  2010cites this paper
• Pharmacokinetics and antisecretory effects of intravenous omeprazole in horses

  2010cites this paper
• Duration of antisecretory effects of oral omeprazole in horses with chronic gastric cannulae

  2010cites this paper
• Chapter 4 – Omeprazole

  2010cites this paper
• A Simple RP-HPLC Method for the Determination of Omeprazole in Human Serum and Urine: Validation and Application in Pharmacokinetic Study

  2010cites this paper
• Effects of intramuscular omeprazole on gastric acid secretion in horses over a twenty-four hour period.

  2010cites this paper
• A comparison of the acid‐inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism

  2010cites this paper
• Improved HPLC method for determination of four PPIs, omeprazole, pantoprazole, lansoprazole and rabeprazole in human plasma.

  2010cites this paper
• Relative bioavailability and pharmacokinetic study of omeprazole 20 mg enteric-coated tablet in healthy Bangladeshi volunteers.

  2009cites this paper
• Bioequivalence and Pharmacokinetic Study of Two Different Omeprazole Capsule Formulations in Healthy Bangladeshi Volunteers

  2009cites this paper
• Calcium Phosphate Cements Loaded with Pantoprazole as Novel Bone Substitutes

  2008cites this paper
• INDIRECT SPECTROFLUORIMETRIC DETERMINATION OF OMEPRAZOLE BY ITS QUENCHING EFFECT ON THE FLUORESCENCE OF T3+-1,10-PHENANTHROLINE COMPLEX IN PRESENCE OF BIS (2-ETHYLHEXYL) SULFOSUCCINATE SODIUM IN CAPSULE FORMULATIONS

  2008influential citation
• Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians.

  2008cites this paper
• Development and Validation of an HPLC Method for the Simultaneous Monitoring of Bromazepam and Omeprazole

  2008cites this paper
• The effect of proton pump inhibitors (PPIs) on the orientation of Helicobacter pylori in the gastric mucus of the Mongolian gerbil in vivo .

  2008cites this paper
• Simultaneous Determination of Omeprazole and Domperidone in Capsules by RP‐HPLC and Densitometric HPTLC

  2007cites this paper
• Rapid determination of omeprazole in human plasma by protein precipitation and liquid chromatography-tandem mass spectrometry.

  2007cites this paper
• Analytical methodologies for the determination of omeprazole: an overview.

  2007cites this paper
• Effect of omeprazole and cimetidine on plasma diazepam levels

  2007cites this paper
• Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole.

  2007cites this paper
• Determination of esomeprazole and its two main metabolites in human, rat and dog plasma by liquid chromatography with tandem mass spectrometry.

  2007cites this paper
• Suppression of gastric acid with intravenous esomeprazole and omeprazole: results of 3 studies in healthy subjects.

  2007cites this paper
• Sensitive determination of omeprazole and its two main metabolites in human plasma by column-switching high-performance liquid chromatography: application to pharmacokinetic study in relation to CYP2C19 genotypes.

  2006cites this paper
• Degradation of lansoprazole and omeprazole in the aquatic environment.

  2006cites this paper
• Studies on drug interactions between esomeprazole, amoxicillin and clarithromycin in healthy subjects.

  2006cites this paper
• Pharmacogenomics in DME

  2006cites this paper
• Determination of omeprazole, hydroxyomeprazole and omeprazole sulfone using automated solid phase extraction and micellar electrokinetic capillary chromatography.

  2006cites this paper
• Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study.

  2006cites this paper
• Sensitive quantification of omeprazole and its metabolites in human plasma by liquid chromatography-mass spectrometry.

  2006cites this paper
• Xenobiotics in the environment: abiotic transformation and toxicity

  2006cites this paper
• Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo

  2006cites this paper
• HPLC Determination of Omeprazole in Human Plasma Using a Monolithic Column

  2006cites this paper
• Determination of omeprazole in human plasma by liquid chromatography-electrospray quadrupole linear ion trap mass spectrometry.

  2005cites this paper
• Effect of a Triphasic Oral Contraceptive on Drug‐Metabolizing Enzyme Activity as Measured by the Validated Cooperstown 5+1 Cocktail

  2005cites this paper
• Degradation of Omeprazole Induced by Enteric Polymer Solutions and Aqueous Dispersions: HPLC Investigations

  2005cites this paper
• Intravenous Esomeprazole 40mg is Effective for the Control of Intragastric Acid Levels Whether Given as a 3-Minute Injection or a 30-Minute Infusion

  2005cites this paper
• Omeprazole raises somatostatin and motilin in human plasma.

  2005cites this paper
• Quantification of omeprazole degradation by enteric coating polymers: an UV-VIS spectroscopy study.

  2005cites this paper
• Lack of Pharmacokinetic Interaction between Esomeprazole and the Nonsteroidal Anti-Inflammatory Drugs Naproxen and Rofecoxib in Healthy Subjects

  2005cites this paper
• Pharmacokinetics of esomeprazole following varying intravenous administration rates.

  2005cites this paper
• Lack of effect of omeprazole, cimetidine, and ranitidine on the pharmacokinetics of ethanol in fasting male volunteers

  2004cites this paper
• A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects

  2004cites this paper
• RELATIVE BIOAVAILABILITY OF OMEPRAZOLE CAPSULES AFTER ORAL DOSING

  2004cites this paper
• Pharmacokinetics of various single intravenous and oral doses of omeprazole

  2004cites this paper
• MEDICINAL PLANTS AND HERBS OF NEWFOUNDLAND. PART 1. CHEMICAL CONSTITUENTS OF THE AERIAL PART OF PINEAPPLE WEED (MATRICARIA MATRICARIOIDES)

  2004cites this paper
• Lack of Weight‐Based Dose Dependency and Intraindividual Variability of Omeprazole for CYP2C19 Phenotyping

  2004cites this paper
• Time‐Dependent Amplified Pharmacokinetic and Pharmacodynamic Responses of Rabeprazole in Cytochrome P450 2C19 Poor Metabolizers

  2003cites this paper
• Inhibitory Potency of Twice-a-Day Omeprazole on Gastric Acidity Is Enhanced by Eradication of H. pylori in Duodenal Ulcer Patients

  2003cites this paper
• Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19.

  2003cites this paper
• The Role of Cytochrome P450 2C19 Activity in Flunitrazepam Metabolism In Vivo

  2003cites this paper
• Acid Inhibitory Potency of Twice a Day Omeprazole is not Affected by Eradication of Helicobacter pylori in Healthy Volunteers

  2003cites this paper
• Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 303 Pharmacodynamic Modelling of Irreversible and Reversible Gastric Proton Pump Inhibitors

  2003cites this paper
• Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N‐acetyltransferase‐2, and xanthine oxidase activities with the “Cooperstown 5+1 cocktail”

  2003cites this paper
• First-order UV-derivative spectrophotometry in the analysis of omeprazole and pantoprazole sodium salt and corresponding impurities.

  2003cites this paper
• Pharmacodynamic Modelling of Irreversible and Reversible Gastric Proton Pump Inhibitors

  2003cites this paper
• Pharmacokinetic study of esomeprazole in patients with hepatic impairment

  2002cites this paper
• The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH

  2002influential citation
• Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker

  2002influential citation
• Phenotype of CYP2C19 and CYP3A4 by determination of omeprazole and its two main metabolites in plasma using liquid chromatography with liquid-liquid extraction.

  2002cites this paper
• Gastric Acid Secretion in the Dog: A Mechanism-Based Pharmacodynamic Model for Histamine Stimulation and Irreversible Inhibition by Omeprazole

  2002cites this paper
• Pharmacokinetics of Omeprazole Given by Continuous Intravenous Infusion to Patients with Varying Degrees of Hepatic Dysfunction

  2002cites this paper
• Improved high performance liquid chromatographic analysis of omeprazole in human plasma.

  2001cites this paper
• Pharmacokinetics and pharmacodynamics of esomeprazole, the S‐isomer of omeprazole

  2001cites this paper
• Omeprazole determination using HPLC with coulometric detection.

  2001cites this paper
• Pharmacokinetic Study of Esomeprazole in the Elderly

  2001cites this paper
• Esomeprazole 40mg Capsules are Bioequivalent when Administered Intact or as the Contents Mixed with Applesauce

  2001cites this paper
• A RAPID HPLC-DAD METHOD FOR SEPARATION AND DETERMINATION OF OMEPRAZOLE EXTRACTED FROM HUMAN PLASMA

  2001cites this paper
• Assay of omeprazole and omeprazole sulfone by semi-microcolumn liquid chromatography with mixed-function precolumn.

  2001cites this paper
• Pharmacokinetics and pharmacodynamics of antiulcer agents in llama.

  2001cites this paper
• Pharmacodynamics and kinetics of omeprazole MUPS 20 mg and pantoprazole 40 mg during repeated oral administration in Helicobacter pylori‐negative subjects

  2000cites this paper
• Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects

  2000cites this paper
• Pharmacokinetics of orally administered omeprazole in children

  2000cites this paper
• Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro‐oesophageal reflux disease

  2000cites this paper
• A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog.

  2000cites this paper
• Studies in Healthy Volunteers do not Show any Electrocardiographic Effects with Esomeprazole

  2000cites this paper
• Determination of the enantiomers of omeprazole in blood plasma by normal-phase liquid chromatography and detection by atmospheric pressure ionization tandem mass spectrometry.

  1999cites this paper
• Comparison of derivative spectrophotometric and liquid chromatographic methods for the determination of omeprazole in aqueous solutions during stability studies.

  1999cites this paper
• CYP2C19 genotypes and omeprazole metabolism after single and repeated dosing when combined with clarithromycin

  1999cites this paper
• PHARMACOKINETICS AND DISPOSITION

  1999cites this paper
• Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole.

  1999cites this paper
• Artemisinin induces omeprazole metabolism in human beings

  1998cites this paper
• Simultaneous determination of omeprazole and 5'-hydroxyomeprazole in human plasma by liquid chromatography-tandem mass spectrometry.

  1998cites this paper
• Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype

  1998cites this paper
• Omeprazole for refractory gastroesophageal reflux disease during pregnancy and lactation.

  1998cites this paper
• Lack of drug-drug interaction between three different non-steroidal anti-inflammatory drugs and omeprazole

  1998cites this paper
• Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.

  1998cites this paper
• CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection.

  1998cites this paper
• Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects

  1997cites this paper